Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Catherine Patte(Institut Gustave Roussy), Mitchell S. Cairo(New York Medical College), Jean Michon(Université Paris Sciences et Lettres), Richard Sposto(Children's Hospital of Los Angeles), Martine Raphaël(University of Lausanne), Mary Gerrard(Sheffield Children's Hospital), Keith McCarthy(National Health Service), Ross Pinkerton(Royal Marsden NHS Foundation Trust), Anne Aupérin(Inserm), Sherrie L. Perkins(University of Utah), Claire Weston(University of Leicester)
Blood
November 28, 2006
Cited by 431


Related Papers